Prof. David Nutt
Prof David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Experimental Medicine at Imperial College London.
He received his undergraduate training in medicine at Cambridge and Guy's Hospital, and continued training in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET.
He is currently Chair of the Independent Scientific Committee on Drugs (ISCD) and President of the European College of Neuropsychopharmacology (ECNP), a council member of the European Brain Council, President-elect of the British Neuroscience Association, the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. In addition, he has edited the Journal of Psychopharmacology for over a decade and acts as the psychiatry advisor to the British National Formulary. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 26 books.
Previously he has been member and Chair of the Advisory Committee on the Misuse of Drugs (ACMD – 1998-2009), President of the British Association of Psychopharmacology (BAP), member of the HEFCE/NHS Senior Lecturer Selection Panel and member of the MRC Neuroscience Board. Other previous national contributions include membership of the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines (2000 – 2005) and member of the Ministry of Defence Science Advisory Board (2005-2007). He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that provided a 25-year vision for this area of science and public policy and in 2006 he was Director of Bristol Neuroscience.
He broadcasts widely to the general public both on radio and television including recent BBC Horizon on drug harms and their classification. He also lecturers widely to the public as well as to the scientific and medical communities; for instance has presented three time at the Cheltenham Science Festival and several times for Café Scientifiques. In 2010 he was listed as one of the 100 most important figures in British Science by The Times Eureka science magazine.
Patrice Boyer, MD, PhD
Patrice Boyer, MD, Ph.D is currently full professor of clinical neurosciences psychopathology and psychiatry at the University of Paris 7- Denis Diderot(France), professor of psychiatry (geographical) at the University of Ottawa, Ontario, Canada, and professor of post graduate studies in the same University.
On a European and international level Professor Boyer is past president of the European Psychiatric Association (EPA) and the chairman of the ECNP networks Initiative (ENI) coordinating 6 research networks in Europe. Prof. Boyer is member of the EPA board and executive committee since June 2000.
On a national level Prof. Boyer is member of the steering committee for the development of the research in clinical neurosciences in the new INSERM-ITMO institute in France (Institut Thématique des Neurosciences, Psychiatrie). He is co-chairman of the Master and Doctorate courses for neurobiology at the Universities of Paris 5 and Paris 7 (France) and he has been the president of the second edition of the French Congress of Psychiatry in Lyon, France (17-20 November 2010). He is now the general co-secretary for this congress.
Prof. Boyer has been trained at the Sainte Anne and Pitié- Salpétrière hospitals in Paris and was previously the research unit director of the schizophrenia Research Unit at the University of Ottawa Institute of Mental Health Research (IMHR), Ontario, Canada.
Pr Boyer has been the founding editor in chief of the journal European Psychiatry and is still member of the editorial board. He was a regional editor for the British Journal of Psychiatry (1989-1999) fostering the collaboration between European Psychiatry and the BJP.
Patrice Boyer is the author of 220 scientific articles (indexation into the «current contents» and «pubmed») of 180 didactic manuscripts and of 20 books.
Vice President Monica Di Luca
Monica Di Luca, MD, PhD, is currently professor of pharmacology and Vice-Director of the Department of Pharmacological Sciences at the University of Milano. She is also president of the Federation of European Neuroscience Societies (FENS), chair of Committee for International Research Programmes of University of Milano and chair for International Research Programmes of Italian Board of Rectors. Her primary research interest is related to brain and synaptic plasticity both in physiological and pathological conditions. In the last 15 years she focused on the understanding of the molecular mechanisms regulating the composition, the structural organization and the dynamic of the glutamatergic synapse. In this frame she was coordinator of one European Commission VI FP project (Synscaff) and of two VII FP projects (REPLACES, cPADS) and partner one VII FP project (SYMBAD). A total of 160 pubmed indexed papers have been published.
Wolfgang H. Oertel, MD, PhD, is Hertie-Senior-Research-Professor (2014-2022), Professor for Neurology and former Chairman (1996-2014) at the Dept. Neurology, Philipps University Marburg, Germany. Currently, he is president of the International REM-Sleep Behaviour Disorder Study Group and treasurer of the Euro-pean Restless Legs Syndrome (RLS) Study group. He chairs the European Afffairs Subcom-mittee (EASC) of the European Academy of Neurology (EAN). Dr. Oertel’s main field of scientific interest are neurodegenerative disorders and related disorders. At present, his focus is on the discovery of prodromal stages of PD, but he also keeps a strong interest in RLS. His over 650 reviewed scientific publications have a h-factor >85.